Develop an oral formulation for monoclonal antibodies
The aim of this project is to develop a novel low-cost vaccine against pneumococcal disease that is suitable to be implemented in the emerging markets, using a new vaccine technology that allows intranasal delivery, low-cost vaccine production and broader protection.
Project ID:
7200